Quick Answer
Cyclerion Therapeutics, Inc. reported Stockholders Equity of $9.09 million for fiscal year 2025.
Cyclerion Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $9.09M | +2.7% |
| 2024 | $8.85M | -21.6% |
| 2023 | $11.29M | +8.0% |
| 2022 | $10.45M | -78.3% |
| 2021 | $48.25M | -18.9% |
| 2020 | $59.49M | -39.1% |
| 2019 | $97.73M | +1035.7% |
| 2018 | -$10.45M | -21.9% |
| 2017 | -$8.57M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $9.54M | +16.3% | +11.3% |
| June 30, 2025 | $8.57M | -2.4% | -2.4% |
| March 31, 2025 | $8.78M | -11.5% | -0.8% |
| December 31, 2024 | $8.85M | -21.6% | +8.0% |
| September 30, 2024 | $8.20M | -36.3% | -6.7% |
| June 30, 2024 | $8.78M | +70.5% | -11.5% |
| March 31, 2024 | $9.92M | +152.8% | -12.1% |
| December 31, 2023 | $11.29M | +8.0% | -12.3% |
- Cyclerion Therapeutics, Inc. showed an increase of +2.7% in Stockholders Equity compared to the prior fiscal year.
- Over the 2017–2025 period, Cyclerion Therapeutics, Inc.’s stockholders equity has grown by 206.0% (from -$8.57 million to $9.09 million).
- The most recent figure is from Cyclerion Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: